BEAM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BEAM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Beam Therapeutics's quarterly accounts payable & accrued expense increased from Sep. 2023 ($26.4 Mil) to Dec. 2023 ($63.4 Mil) but then declined from Dec. 2023 ($63.4 Mil) to Mar. 2024 ($57.3 Mil).
Beam Therapeutics's annual accounts payable & accrued expense declined from Dec. 2021 ($56.5 Mil) to Dec. 2022 ($27.6 Mil) but then increased from Dec. 2022 ($27.6 Mil) to Dec. 2023 ($63.4 Mil).
The historical data trend for Beam Therapeutics's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Accounts Payable & Accrued Expense | Get a 7-Day Free Trial | 10.94 | 12.96 | 56.51 | 27.56 | 63.35 |
Beam Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Accounts Payable & Accrued Expense | Get a 7-Day Free Trial | 35.19 | 26.96 | 26.43 | 63.35 | 57.30 |
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
Christine Bellon | officer: Chief Legal Officer | BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142 |
Amy Simon | officer: Chief Medical Officer | BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142 |
Giuseppe Ciaramella | officer: President & CSO | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
John M. Evans | director, officer: CEO | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Terry-ann Burrell | officer: CFO | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Fmr Llc | 10 percent owner, other: See Remark 1 | 245 SUMMER STREET, BOSTON MA 02210 |
John Maraganore | director | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
Graham K Cooper | director | C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
Kathleen E Walsh | director | C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001 |
Arch Venture Fund Ix Overage, L.p. | 10 percent owner | 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631 |
Stephen C Knight | director | C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142 |
Mark Fishman | director | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Arch Venture Partners Ix, Llc | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Ix, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Ix Overage, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By Value_Insider Value_Insider • 11-07-2022
By sperokesalga sperokesalga • 03-27-2023
By Value_Insider Value_Insider • 12-10-2022
By Value_Insider Value_Insider • 11-14-2022
By Marketwired • 09-05-2023
By PRNewswire • 12-08-2023
By Stock market mentor Stock market mentor • 01-03-2023
By Value_Insider Value_Insider • 12-02-2022
By PRNewswire • 12-11-2023
By Value_Insider Value_Insider • 11-30-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.